Anzeige
Mehr »
Login
Donnerstag, 13.03.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Aktie des Tages: Die nächste Chance auf einen potentiellen Multi-Tenbagger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
Lang & Schwarz
13.03.25
07:00 Uhr
1,089 Euro
-1,089
-100,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0741,10407:00
0,0000,00007:30

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
DiD. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. in Connection with its up to $15.0 Million Private Placement216HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...
► Artikel lesen
DiPlus Therapeutics Regains Nasdaq Compliance327WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) announced that on March 7, 2025, Nasdaq confirmed the company's compliance with the minimum stockholders' equity requirement.As a result, PSTV...
► Artikel lesen
MoPlus Therapeutics regains compliance with Nasdaq minimum stockholders' equity requirement9
MoPlus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement90HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...
► Artikel lesen
FrWhy Plus Therapeutics, Inc. (PSTV) Soared on Thursday10
FrPSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy8
FrPre-market Movers: Intuitive Machines, Plus Therapeutics, GEN Restaurant Group, Hewlett Packard Enterprise, The Gap, Inc.379OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.25 A.M. ET).In the Green Plus Therapeutics, Inc. (PSTV) is up over 33% at $1.92. GEN...
► Artikel lesen
FrPlus Therapeutics Inc.: Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma112Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall...
► Artikel lesen
FrFDA ODD given to Plus Therapeutics' injectable radiotherapy11
06.03.Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment16
06.03.Plus Therapeutics Gets FDA ODD For Rhenium (186Re) Obisbemeda; Stock Surges In Pre-market8
06.03.FDA erteilt Plus Therapeutics' Krebsbehandlung Orphan-Drug-Status8
06.03.FDA grants orphan drug status to Plus Therapeutics' cancer treatment3
06.03.Plus Therapeutics Inc.: Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer112HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...
► Artikel lesen
04.03.Plus Therapeutics tumbles on $15M private placement9
04.03.Plus Therapeutics Inc.: Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds5
04.03.PLUS THERAPEUTICS, INC. - 8-K, Current Report3
26.02.Plus Therapeutics sets dose for CNS cancer treatment trial16
26.02.Plus Therapeutics Inc.: Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases421AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...
► Artikel lesen
24.02.XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION860DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME...
► Artikel lesen
Seite:  Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1